Opinion

Video

First-Line Therapy for Chronic GvHD

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
Related Content
Image Credit: © Corona Borealis - stock.adobe.com
March 18th 2025

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Orca-T in Hematologic Malignancies
March 17th 2025

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

Acute Myeloid Leukemia | Image Credit: © stock.adobe.com
March 12th 2025

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML